 BERKELEY, Calif., Sept. 29, 2021 GLOBE NEWSWIRE -- Caribou Biosciences, Inc. Nasdaq:CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ran Zheng to its board of directors. Ms. Zheng brings over 25 years of biotechnology industry leadership experience in biologics drug development with broad expertise in technical operations and the manufacture of gene and cell therapies. 